
Allena Pharmaceuticals ALNA
Quartalsbericht 2022-Q2
hinzugefügt 15.08.2022
Allena Pharmaceuticals Betriebsaufwand 2011-2026 | ALNA
Betriebsaufwand Jährlich Allena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 47.6 M | 32 M | 46.9 M | 35.6 M | 21 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 47.6 M | 21 M | 36.6 M |
Betriebsaufwand Vierteljährlich Allena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 6.92 M | 11.6 M | 10.1 M | 12.4 M | 13.7 M | 11.4 M | 9.98 M | 7.92 M | 6.56 M | 7.52 M | 11.3 M | 13.3 M | 11.3 M | 11.6 M | 9.78 M | 9.7 M | 8.14 M | 7.97 M | 6.57 M | 4.36 M | 4.48 M | 5.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13.7 M | 4.36 M | 9.19 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.68 | 2.44 % | $ 429 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Kamada Ltd.
KMDA
|
69 K | $ 8.81 | 1.73 % | $ 260 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.28 | -2.62 % | $ 7.89 B | ||
|
Evogene Ltd.
EVGN
|
28 M | $ 0.81 | -9.28 % | $ 27.9 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
11.7 M | - | -19.68 % | $ 18.4 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Aptorum Group Limited
APM
|
20.7 M | $ 0.79 | -1.29 % | $ 4.31 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
842 K | $ 0.88 | -1.43 % | $ 442 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 224.42 | -2.52 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | ||
|
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 4.13 | 0.12 % | $ 352 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.36 | 2.27 % | $ 14.8 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Codexis
CDXS
|
31.5 M | $ 1.17 | -0.85 % | $ 85.9 M | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 110.12 | -0.28 % | $ 27.2 B | ||
|
Amneal Pharmaceuticals
AMRX
|
539 M | $ 14.49 | -0.75 % | $ 4.48 B | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M |